Dallas – September 18, 2026 -- Nanoscope Therapeutics will unveil four-year follow-up data showing sustained visual acuity gains from its gene therapy MOGENRY® in retinitis pigmentosa patients, with the FDA already having accepted and filed the company's Biologics License Application.
Christine Kay to present long-term durability data at Retina Society meeting
Dr. Christine Kay, Director of Clinical Research and Retinal Genetics at Vitreoretinal Associates in Gainesville, will present the data on September 23, 2026, at the 59th Annual Scientific Meeting of the Retina Society in Los Angeles. The presentation, titled "Lasting Vision Improvement With MCO-010 Optogenetic Therapy," draws on the REMAIN 4-year extension of the RESTORE Phase 2b/3 trial (NCT04945772) and is scheduled for 3:15 PM PT at the Fairmont Century Plaza Hotel.
MOGENRY® is the only program to demonstrate sustained visual acuity restoration at four years, per the company
Nanoscope states that patients dosed with MOGENRY® (sonpiretigene isteparvovec, MCO-010) continue to maintain visual acuity gains well beyond initial treatment, distinguishing the therapy from other programs in the optogenetic and gene-therapy space for inherited retinal disease. The FDA's acceptance and filing of the BLA moves the one-time, in-office intravitreal therapy closer to potential approval as a treatment for retinitis pigmentosa.
Therapy avoids genetic testing and surgery, targeting existing retina clinic workflows
MOGENRY® delivers a multi-characteristic opsin gene to bipolar retinal cells, making surviving cells directly light-sensitive after photoreceptor loss. The therapy requires no genetic testing, no invasive surgery, and no repeat dosing, and is designed for administration within standard retina office settings—a commercial differentiator for payers and clinics evaluating adoption costs.
Pipeline expansion targets Stargardt disease and geographic atrophy
Beyond RP, Nanoscope's MCO-010 has shown results in the STARLIGHT Phase 2 trial for Stargardt disease (NCT05417126), with a Phase 3 registrational trial planned for initiation in 2026. The compound holds FDA Fast Track, Orphan Drug, and RMAT designations for Stargardt disease, plus EMA Orphan designations for rod- and cone-dominant dystrophies. Sakigake and Orphan designations have also been granted in Japan, and an Orphan designation in Saudi Arabia. A Phase 2 program in geographic atrophy is expected to start in 2026, alongside an IND-ready program for Leber congenital amaurosis.